Effect of GFR and UAC to evaluate renal function in patients with type 2 diabetes
FU Ting1,LI Jinghua1,QI Yue2,and WANG Suli1
1.Department of Endocrinology,2.Department of Cardiology, Affiliated Hospital of Logistics University of Chinese People’s Armed Police Forces, Tianjin 300162,China
Abstract：Objective Through the analysis of glomerular filtration rate (GFR) and urinary albumin concentration (UAC) in 110 patients with type 2 diabetes, to discuss whether there is relevance between GFR and UAC in patients with type 2 diabetes and its application value. Methods One hundred and ten patients with type 2 diabetes were enrolled in this study. All of the patients received measurement of morning urine trace albumin concentration, and renal dynamic imaging examination. General clinical data were collected. Results UAC value was negatively related to GFR value(P<0.05).When GFR<60 ml/(min·1.73 m2), with GFR value as the gold standard, ROC curves showed that the optimal UAC value cut-off values were 10.90 mg/L by maximizing the sum of sensitivity and specificity. In GFR≥60 ml/(min·1.73 m2)group,the incidence of hypertension in patients with normal UAC value was higher than that in UAC abnormal patients(P<0.05). Conclusions In patients with type 2 diabetes, by the rise of UAC value,GFR value would come down. To some extent, UAC value can reflect the renal function changes in patients,but the evaluation of renal function in patients with type 2 diabetes should not be based on the traditional standard (UAC<30 mg/L)as the boundary, in some patients GFR value decreased obviously [GFR < 60 ml/(min·1.73 m2)] wheras UAC value can still be in a normal level. We need to focus on albuminuria and glomerular filtration rate at the same time in the clinical work in patients with type 2 diabetes especially in elderly patients with a history of high blood pressure in order to avoid misdiagnosis or missed diagnosis.
符婷, 李敬华, 齐跃, 王素莉. GFR与UAC对2型糖尿病肾功能评价的价值[J]. 武警医学, 2016, 27(3): 233-236.
FU Ting,LI Jinghua,QI Yue,and WANG Suli. Effect of GFR and UAC to evaluate renal function in patients with type 2 diabetes. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(3): 233-236.
Collins A J, Foley RN, Chavers B, et al. 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States[J]. Am J Kidney Dis, 2012,59(1 Suppl 1):A7, e1-420.
[2]
Mogensen C E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes[J]. N Engl J Med, 1984,310(6):356-360.
[3]
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Am J Kidney Dis, 2002,39(2 Suppl 1):S1-266.
[4]
Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?[J]. Diabet Med, 2008,25 Suppl 2:25-29.
[5]
de Boer I H, Rue T C, Cleary P A, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort[J]. Arch Intern Med, 2011,171(5):412-420.
[6]
Derhaschnig U, Kittler H, Woisetschlager C, et al. Microalbumin measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertension patients?[J]. Nephrol Dial Transplant, 2002,17(1):81-85.
Yamagishi S, Matsui T. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy[J]. Curr Pharm Biotechnol, 2011,12(3):362-368.
[11]
李 竞,毛拓华.糖尿病微血管病变[J]. 微循环学杂志,2013,23(2):1-4.
[12]
de Zeeuw D, Parving H H, Henning R H. Microalbuminuria as an early marker for cardiovascular disease[J]. J Am Soc Nephrol, 2006,17(8):2100-2105.
[13]
Thomas M C. Anemia in diabetes: marker or mediator of microvascular disease?[J]. Nat Clin Pract Nephrol, 2007,3(1):20-30.
[14]
Ekundayo O J, Muchimba M, Aban I B, et al. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure[J]. Am J Cardiol, 2009,103(1):88-92.
[15]
So W Y, Kong A P, Ma R C, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients[J]. Diabetes Care, 2006,29(9):2046-2052.
[16]
McCullough P A, Li S, Jurkovitz C T, et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality[J]. Am Heart J, 2008,156(2):277-283.
[17]
Thomas M C, Macisaac R J, Jerums G, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON]11)[J]. Diabetes Care, 2009,32(8):1497-1502.
[18]
Yokoyama H, Sone H, Oishi M, et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15)[J]. Nephrol Dial Transplant, 2009,24(4):1212-1219.
[19]
Ohta M, Babazono T, Uchigata Y, et al. Comparison of the prevalence of chronic kidney disease in Japanese patients with Type 1 and Type 2 diabetes[J].Diabet Med, 2010,27(9):1017-1023.
[20]
Macisaac RJ, Jerums G. Albuminuric and non-albuminuric pathways to renal impairment in diabetes[J].Minerva Endocrinol, 2005,30(3):161-177.
2016, Vol. 27 
